RT @Genmab: Our DuoBody® platform draws inspiration from nature to enable the discovery of #bispecific antibodies for the treatment of #can…
We are pleased to announce publication of preclinical data evaluating potential antitumor activity of epcoritamab in Blood Cancer Journal https://t.co/yt4xWgrJEP, helping to move #bloodcancer research forward. #CancerResearch https://t.co/n3qAO4J5da
Our DuoBody® platform draws inspiration from nature to enable the discovery of #bispecific antibodies for the treatment of #cancer. See results from preclinical evaluation of bispecific antibody epcoritamab in Blood Cancer Journal https://t.co/yt4xWgrJEP.
Genmab announces publication in Blood Cancer Journal https://t.co/yt4xWgrJEP evaluating potential of preclinical, anti-tumor activity of epcoritamab in DLBCL, FL, MCL. Congratulations to Hilma Van der Horst and team on this important publication. #CancerRe